Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma

Paul, Shashi; Sharma, Hunny

doi:10.1016/j.jceh.2014.03.048

Cited by 28 publications

(18 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following ablation, the lesions are monitored using either contrast-enhanced CT or MRI to ensure the lesions have undergone total necrosis and to ensure there is no residual tumour, which would otherwise continue to grow (Figure 2). 22 SIRT generally has few risks of complications. It can cause unspecific symptoms such as fever, nausea, pain, fatigue and anorexia.…”

Section: Transarterial Embolizationmentioning

confidence: 99%

See 1 more Smart Citation

Current strategies in interventional oncology of colorectal liver metastases

Gruber‐Rouh

Marko

Thalhammer

et al. 2016

BJR

View full text Add to dashboard Cite

The adequate treatment of non-resectable liver metastases from colorectal cancer which are resistant to systemic chemotherapy currently provides a great challenge. The aim is to identify and review key strategies in the treatment of colorectal liver metastases. A search for current literature on the topic of interventional strategies for colorectal metastases was performed in Medline in order to achieve this goal. Studies before 2005 and with ,20 patients treated for colorectal metastases were excluded. Transarterial chemoembolization (TACE), transarterial embolization and selective internal radiation therapy (SIRT) were identified as examples of regional strategies for colorectal liver metastases, utilizing the unique blood supply of the liver. Radiofrequency ablation (RFA), microwave ablation (MWA) and cryoablation were selected as examples for currently available ablative techniques. Median survival in the key studies reviewed ranged from 7.7 to 28.6 for TACE, 8.3-12.6 for SIRT, 8.2-53.2 for RFA and 29-43 months for MWA. After review of the literature, it can be concluded that interventional oncologic therapies are a safe and effective method for treating colorectal liver metastases. The use of new chemotherapeutic agents for local therapy and new ablation technologies and techniques may increase patient survival and allows a neoadjuvant therapy setting. In addition, a combination of local therapies may be used to increase effectiveness in the future, which is subject to further research. INTRODUCTIONColorectal cancer is one of the most common cancers that shows fatal progression.1 Colorectal carcinoma most commonly metastasises to the liver due to haematogenous spread.2 At the time of diagnosis, 20-30% of patients have liver metastases, and during the course of disease, up to 60% of patients develop hepatic metastases.3 Although surgical excision is the first-line treatment for colorectal metastases, only 10-25% of patients are candidates for surgical resection. 4 Neoadjuvant systemic chemotherapy only allows 10-30% of patients with unresectable colorectal liver metastases sufficient downsizing for resection.

show abstract

Section: Transarterial Embolizationmentioning

confidence: 99%

“…27 Thereafter lesions are generally monitored using contrast CT and MRI. 22 The most common complications during RFA are bile duct injury, haemorrhage, liver infarction and refractory pleural effusions. Intraperitoneal haemorrhage can be a fatal complication of RFA (Table 3).…”

Section: Transarterial Embolizationmentioning

confidence: 99%

Current strategies in interventional oncology of colorectal liver metastases

Gruber‐Rouh

Marko

Thalhammer

et al. 2016

BJR

View full text Add to dashboard Cite

show abstract

“…It has been used in intermediate HCC that we have few choices of treatment. 12,13 The main concept of chemoembolization is to emboli the hepatic artery which is the main hepatic tumour vessel. This procedure may cause tumour death without affecting normal tissue.…”

Section: Tacementioning

confidence: 99%

“…There are not noteworthy superiority reported on using specific chemotherapy agent in TACE. 13 A systematic review of 15 studies comparing TACE with conservative management had reported that the patients with portal vein branch invasion and well liver function may achieve optimal advantage from treatment with TACE. 16 Another systematic review on five randomized trials compared TACE with and without chemotherapy treatment.…”

Section: Tacementioning

confidence: 99%

New modalities of treatment for hepatocellular carcinoma

Behnagh

Rezaei

Jahannia

et al. 2017

J. contemp. med. sci.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the second most common cause of death from cancer worldwide. Managing HCC is difficult. However, there are many treatment options available such as liver transplantation, radiotherapy, different ablative techniques, surgery, trans-arterial chemoembolization (TACE) and systemic therapy. These treatments did not show the promising responses and the recurrence rate is still high. On the other hand, there are some new treatments such as immunotherapy, gene therapy, combination of different therapies, Chinese traditional therapies and new targeted therapies. The aim of this study is to review both the recent changes in the common therapies and newly developed therapies of HCC.

show abstract

“…There are 3 primary interventional radiologic treatment methods for HCC: (1) percutaneous ablative procedures, (2) chemoembolization, and (3) radioembolization. 2,3 …”

Section: Introductionmentioning

confidence: 99%

Untitled

Boyvat

2017

Exp Clin Transplant

View full text Add to dashboard Cite

The current treatment modalities for patients with hepatocellular carcinoma are discussed in this review. Hepatocellular carcinoma arises in up to 90% of cirrhotic patients, mainly due to chronic viral hepatitis and alcohol abuse. Nearly two-thirds of all patients with hepatocellular carcinoma are diagnosed at advanced stages, thus causing problems with treatment. Regardless of the stage of the disease, interventional radiology offers both curative and palliative treatment options in the management of this disease. Selecting the most appropriate treatment requires an initial staging assessment and detailed clinical and radiologic workup. Treatment allocation is based on liver function, size and number of tumors, macrovascular invasion, and extrahepatic spread of disease.

show abstract

Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma

Cited by 28 publications

References 111 publications

Current strategies in interventional oncology of colorectal liver metastases

Current strategies in interventional oncology of colorectal liver metastases

New modalities of treatment for hepatocellular carcinoma

Untitled

Contact Info

Product

Resources

About